Drug Profile
Ombitasvir - monotherapy
Alternative Names: ABT-267Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Anilides; Antivirals; Aza compounds; Carbamates; Pyrrolidines
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C